The association between naltrexone treatment and symptoms of depression in opioid-dependent patients
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the change in total symptoms, and symptom clusters, of depression in newly abstinent opioid-dependent individuals being treated with depot naltrexone (Depotrex; Biotek, Inc., Wellesley, MA). METHOD: In a series of opioid-dependent patients (N = 34) treated with naltrexone maintenance and relapse prevention therapy, mood was assessed with a 17-item Hamilton Depression (HAM-D) Scale and subscale scores at baseline, and after naltrexone induction at 2- and 4-week post-baseline. Data were analyzed using generalized estimated equation (GEE) models. RESULTS: Patients demonstrated high baseline affective burden and significant improvement of depression scores over a 4-week period post-baseline (F(2.66) = 8.88; p = .0004). Somatic and cognitive-affective subscale scores significantly declined as well as the seven individual item scores. By contrast, the "late insomnia" item score significantly increased at 2 weeks post-baseline. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Naltrexone induction and maintenance in newly abstinent opioid-dependent individuals does not appear to be associated with worsening of depression; however, it may be associated with sleep impairment early in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shafer, A. B. (2006) · Journal of Clinical Psychology · doi:10.1002/jclp.20213 · Cited by 837 · cited 1×
“These assignments were based on a prior metaanalysis of factor analyses of these items that resulted in loading into four categories: anxiety, depression, insomnia, and somatic (20).”
MethodDepot naltrexone: long-lasting antagonism of the effects of heroin in humans
Comer, S., Collins, E., Kleber, H., Nuwayser, E., Kerrigan, J., & Fischman, M. (2002) · Psychopharmacology · doi:10.1007/s002130100909 · Cited by 175 · cited 1×
“It has been demonstrated that a single injection of depot naltrexone maintains therapeutic efficacy through 4 weeks (15).”
BackgroundA systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence
Kirchmayer, U., Davoli, M., Verster, A. D., Amato, L., Ferri, A., & Perucci, C. A. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00217.x · Cited by 106
Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression
Petrakis, I., Ralevski, E., Nich, C., Levinson, C., Carroll, K., Poling, J., & Rounsaville, B. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b13e3180337fcb · Cited by 66 · cited 1×
“” On the other hand, a double-blind randomized controlled trial comparing naltrexone to disulfiram and placebo for the treatment of alcohol dependence found that naltrexone was associated with improved depressive symptoms over 12 weeks in patients with baseline current depression (12).”
Background
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Latif, Z.-E.-H., Šaltyte Benth, J., Solli, K. K., Opheim, A., Kunoe, N., Krajci, P., Sharma-Haase, K., & Tanum, L. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3537 · Cited by 64
Pharmacotherapy for alcohol use disorder.
Holt, S. R., & Tobin, D. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.008 · Cited by 17
Metadata
- Authors
- Mysels, D. J., Cheng, W. Y., Nunes, E. V., & Sullivan, M. A.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2010-12-30
- Volume
- 37
- Issue
- 1
- Pages
- 22-26
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- OpenAlex
- W2053270944
- Cited by
- 38
- References
- 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. https://app.cochat.ai/papers/10.3109/00952990.2010.540281
- The paper
- Mysels, D. J., Cheng, W. Y., Nunes, E. V., & Sullivan, M. A. (2011). The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.3109/00952990.2010.540281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.